Regional health officials and Farmaindustria meet to analyse new pharmaceutical regulations, the proper use of medicines and advances in digital health
The Regional Minister of Health of Cantabria, César Pascual, inaugurates the 25th CAAC-Pharmaindustry Forum.
‘When we work together, not only do we promote research and biomedical advances, but we also favour the sustainability of health systems’, stressed the president of Farmaindustria, Fina Lladós.
Farmaindustria.es
Santander has hosted this Friday the XXV Forum of Autonomous Communities-Pharmaindustry, a working meeting for analysis, dialogue and collaboration in which thirty health officials from sixteen of the seventeen autonomous communities and representatives of the Association have participated.
The forum was inaugurated by the Regional Minister of Health of Cantabria, César Pascual, and the President of Farmaindustria and CEO of Amgen in Spain, Fina Lladós Canela, who underlined the value of public-private collaboration and the crucial moment for healthcare systems that the confluence of a new regulatory environment, the biomedical revolution thanks to precision medicine, the necessary economic sustainability and digital transformation with the application of artificial intelligence represent.
‘When we work together, we not only boost research and biomedical advances, but we also promote the sustainability of health systems. Through strategic agreements, we can ensure that innovative treatments reach those who need them most,’ said the president of Farmaindustria.
Farmaindustria’s Director General, Juan Yermo, began by putting on the table the challenges and opportunities for pharmaceutical innovation in a new regulatory context, which will be marked by the future Draft Bill on Medicines and Medical Devices and the two Royal Decrees on the Evaluation of Health Technologies and Price and Financing.
These regulatory developments have been addressed by the Director General of Pharmacy of the Valencian Community, Elena Gras, and the Director General of Health of Navarra, Antonio López, while the Director General of Healthcare of the Galician Health Service, Alfredo Silva, has reviewed the care models based on health outcomes that apply in his community.
Pharmaceutical companies need agility and objectivity in decision-making and stability, predictability and regulatory clarity to achieve effective public-private collaboration, said Yermo. ‘These would be the best foundations to address the opportunities we have: to be leaders in access to innovation, as we already are in clinical research, without compromising sustainability; to create a powerful biopharmaceutical innovation ecosystem in our country; and to strengthen Spain’s role as a platform for drug production that guarantees supply and our open strategic autonomy,’ he said.
The meeting was also attended by the Secretary General for Digital Health, Information and Innovation of the National Health System of the Ministry of Health, Juan Fernando Muñoz Montalvo, who highlighted the advances in the Digital Health Strategy and explained the potential of the use of health data for the treatment of patients and improvement of the quality of care in health systems.
Finally, the Director General of Pharmacy, Humanisation and Social and Health Coordination of Cantabria, Isabel Priede, and the Director General of Health Planning of Asturias, Montserrat Bango, discussed experiences on the rational use of medicines in the autonomous communities.
Farmaindustria.es
